Matthew Fisher Sarcoma Research Fund

Matt was diagnosed with a rare aggressive cancer rhabdomyosarcoma in February 2020, and unfortunately this has proved to be terminal. Matt’s down-to-earth and caring nature for his family (wife Naomi, two daughters Vivi and Sylvie), friends and work colleagues is well known. Now we’d like to support Matt’s final wish for increased sarcoma research.

Throughout his treatment in 2020, Matt continued to be your typical chemical patent examiner and would research the patents on his chemotherapy drugs and relay what he found to his oncologist, who believed one was an invention stolen from Australia.

Given his scientific research background, it's no surprise that his final wish was to support critical research required to change the current trajectory for patients living with a sarcoma diagnosis.

All raised funds will be passed to The Cooper Rice-Brading Foundation, which is currently seeking funds for the a world first IL23  sarcoma clinical study in conjunction with the Garvan Institute of Medical Research. This fund is being named in Matt’s honour.

For more information on the The Matthew Fisher Sarcoma Research Fund, please visit  https://www.crbf.org.au/matthew-fisher-sarcoma-research-fund/